CN103958514B - 抗微生物化合物及制备和使用所述化合物的方法 - Google Patents

抗微生物化合物及制备和使用所述化合物的方法 Download PDF

Info

Publication number
CN103958514B
CN103958514B CN201280029215.5A CN201280029215A CN103958514B CN 103958514 B CN103958514 B CN 103958514B CN 201280029215 A CN201280029215 A CN 201280029215A CN 103958514 B CN103958514 B CN 103958514B
Authority
CN
China
Prior art keywords
compound
tautomer
pharmaceutically acceptable
acceptable salt
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280029215.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103958514A (zh
Inventor
E.M.杜菲
A.巴塔查吉
S.陈
Z.F.肯尤
Y.唐
M.谢德曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Rib X Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rib X Pharmaceuticals Inc filed Critical Rib X Pharmaceuticals Inc
Priority to CN201810630324.1A priority Critical patent/CN109053695A/zh
Publication of CN103958514A publication Critical patent/CN103958514A/zh
Application granted granted Critical
Publication of CN103958514B publication Critical patent/CN103958514B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C07D239/36—One oxygen atom as doubly bound oxygen atom or as unsubstituted hydroxy radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201280029215.5A 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法 Expired - Fee Related CN103958514B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810630324.1A CN109053695A (zh) 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US201161476138P 2011-04-15 2011-04-15
US61/476138 2011-04-15
US61/476,138 2011-04-15
US201161535118P 2011-09-15 2011-09-15
US61/535,118 2011-09-15
US61/535118 2011-09-15
US201261610363P 2012-03-13 2012-03-13
US61/610,363 2012-03-13
US61/610363 2012-03-13
PCT/US2012/032994 WO2012173689A2 (en) 2011-04-15 2012-04-11 Antimicrobial compounds and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810630324.1A Division CN109053695A (zh) 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法

Publications (2)

Publication Number Publication Date
CN103958514A CN103958514A (zh) 2014-07-30
CN103958514B true CN103958514B (zh) 2018-07-03

Family

ID=47357660

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280029215.5A Expired - Fee Related CN103958514B (zh) 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法
CN201810630324.1A Pending CN109053695A (zh) 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810630324.1A Pending CN109053695A (zh) 2011-04-15 2012-04-11 抗微生物化合物及制备和使用所述化合物的方法

Country Status (21)

Country Link
US (2) US9221827B2 (cg-RX-API-DMAC10.html)
EP (2) EP3404028A1 (cg-RX-API-DMAC10.html)
JP (2) JP6317669B2 (cg-RX-API-DMAC10.html)
KR (1) KR20140065378A (cg-RX-API-DMAC10.html)
CN (2) CN103958514B (cg-RX-API-DMAC10.html)
AR (1) AR088781A1 (cg-RX-API-DMAC10.html)
AU (3) AU2012271228B2 (cg-RX-API-DMAC10.html)
BR (1) BR112013026410A2 (cg-RX-API-DMAC10.html)
CA (1) CA2833169A1 (cg-RX-API-DMAC10.html)
DK (1) DK2697229T3 (cg-RX-API-DMAC10.html)
EA (1) EA201391536A1 (cg-RX-API-DMAC10.html)
ES (1) ES2665988T3 (cg-RX-API-DMAC10.html)
HU (1) HUE036755T2 (cg-RX-API-DMAC10.html)
IL (1) IL228845A0 (cg-RX-API-DMAC10.html)
MX (1) MX357903B (cg-RX-API-DMAC10.html)
MY (1) MY173518A (cg-RX-API-DMAC10.html)
PH (1) PH12013502135A1 (cg-RX-API-DMAC10.html)
PT (1) PT2697229T (cg-RX-API-DMAC10.html)
SG (2) SG194489A1 (cg-RX-API-DMAC10.html)
TW (2) TW201843154A (cg-RX-API-DMAC10.html)
WO (1) WO2012173689A2 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0739738Y2 (ja) 1989-10-03 1995-09-13 三菱農機株式会社 機体転倒防止装置
JP6274723B2 (ja) 2009-10-16 2018-02-07 メリンタ セラピューティクス,インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
EP3406613A1 (en) 2009-10-16 2018-11-28 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
JP2013508299A (ja) 2009-10-16 2013-03-07 リブ−エックス ファーマシューティカルズ,インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
EP3404028A1 (en) 2011-04-15 2018-11-21 Melinta Therapeutics, Inc. Methods of making antimicrobial compounds
US9346802B2 (en) 2013-03-15 2016-05-24 Epizyme, Inc. CARM1 inhibitors and uses thereof
EP2970266B1 (en) 2013-03-15 2018-01-31 Epizyme, Inc. 1-phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof
WO2014144169A1 (en) 2013-03-15 2014-09-18 Epizyme, Inc. Carm1 inhibitors and uses thereof
MX2016002975A (es) * 2013-09-09 2016-10-21 Melinta Therapeutics Inc Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos.
US9937183B2 (en) 2013-09-09 2018-04-10 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US20180141897A1 (en) 2014-12-08 2018-05-24 The Research Foundation For The State University Of New York Anti-fungals targeting the synthesis of fungal shingolipids
WO2016145417A1 (en) * 2015-03-11 2016-09-15 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
CN105669519B (zh) * 2016-01-04 2018-01-05 北方民族大学 吲哚类化合物、制备方法及其作为抗耐药菌药物的应用
EP3452478A1 (en) 2016-05-06 2019-03-13 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same
US10934295B2 (en) * 2016-05-06 2021-03-02 BioVersys AG Antimicrobials and methods of making and using same
US11098047B2 (en) * 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
EP3638649A4 (en) 2017-06-16 2021-03-17 The Research Foundation for The State University of New York FUNGUSKID AGENTS AGAINST THE SYNTHESIS OF FUNGAL SHINGOLIPIDS
EP3642205A1 (en) 2017-06-19 2020-04-29 Erin M. Duffy Antimicrobials and methods of making and using same
WO2019164880A1 (en) * 2018-02-21 2019-08-29 Duffy Erin M Antimicrobials and methods of making and using same
WO2019234508A1 (en) 2018-06-06 2019-12-12 BioVersys AG Biodefense agents
US20210253589A1 (en) 2018-06-06 2021-08-19 BioVersys AG Aminomethylamidine and methylamidine antimicrobial compounds
WO2020115547A2 (en) * 2018-12-07 2020-06-11 BioVersys AG Pyrrolo[2,3-d]pyrimidin-2-one antimicrobial compounds
CA3126815A1 (en) 2019-01-16 2020-07-23 Curza Global, Llc Antimicrobial compounds and methods
JP2022518230A (ja) 2019-01-16 2022-03-14 カーザ グローバル, エルエルシー 抗菌化合物及び方法
CA3158103A1 (en) * 2019-11-13 2021-05-20 Curza Global, Llc Antimicrobial compounds and methods
CN111254091B (zh) * 2020-01-20 2022-04-19 浙江工业大学 一种嗜麦芽窄食单胞菌gyh及其在降解氯代烃类污染物中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060825A1 (en) * 2000-02-17 2001-08-23 Sk Chemicals Co., Ltd. Pyrrolopyrimidinone derivatives, process of preparation and use
CN1871240A (zh) * 2003-08-26 2006-11-29 帝人制药株式会社 吡咯并嘧啶酮衍生物
CN101535311A (zh) * 2006-07-03 2009-09-16 Sk化学株式会社 吡咯并嘧啶酮衍生物的盐及其制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP2873340B2 (ja) 1988-04-29 1999-03-24 武田薬品工業株式会社 抗生物質tan―1057,その製造法および用途
US5958930A (en) 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
GB9708611D0 (en) 1997-04-28 1997-06-18 Univ Cardiff Chemical compounds
EP1003727A1 (en) 1997-08-07 2000-05-31 Research Corporation Technologies Antibiotic for methicillin resistant bacteria
DE19838998A1 (de) 1998-08-27 2000-03-09 Bayer Ag Neue Naturstoffderivate
EP1113008A1 (en) 1999-12-29 2001-07-04 Pfizer Products Inc. 4-oxo-2-ureido-1,4,5,6-tetrahydro-pyrimidine derivatives useful as antibacterial and antiprotozoal agents
DE10061538A1 (de) 2000-12-11 2002-06-20 Bayer Ag Ureido-Dihydropyrimidinone
DE10061542A1 (de) 2000-12-11 2002-06-13 Bayer Ag Alkanoylamino-pyrimidine
DE10061541A1 (de) 2000-12-11 2002-06-20 Bayer Ag Arylamino-Dihydropyrimidinone
DE10061537A1 (de) 2000-12-11 2002-06-20 Bayer Ag beta-Alanin-Derivate
US6900215B2 (en) 2000-12-15 2005-05-31 Merck Sharp & Dohme Ltd. Imidazo-pyrimidine derivatives as ligands for gaba receptors
DE10133277A1 (de) 2001-07-09 2003-01-23 Bayer Ag ß-Alanin-Derivate
DE10141271A1 (de) 2001-08-23 2003-03-06 Bayer Ag Neue Tetrahydro-1,3,5-triazin-2-on-Derivate und ihre Verwendung
DE10208256A1 (de) 2002-02-26 2003-09-04 Bayer Ag Piperidinouracile
WO2004080466A1 (en) 2003-03-07 2004-09-23 Ribapharm Inc. Cytidine analogs and methods of use
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
CA2666696C (en) * 2006-07-03 2013-01-15 Sk Chemicals Co., Ltd. Salts of pyrrolopyrimidinone derivatives and process for preparing the same
WO2008082440A2 (en) 2006-08-25 2008-07-10 Emory University Fluorescent nucleoside analogues
ES2362805T3 (es) * 2006-09-07 2011-07-13 Industrial Research Limited Inhibidores aminoacíclicos de nucleósido fosforilasas e hidrolasas.
JP2008222557A (ja) 2007-03-08 2008-09-25 Kotobuki Seiyaku Kk ピロロ[3,2−d]ピリミジン誘導体及びこれを有効成分とする医薬組成物
CA2691987C (en) 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
GB0724342D0 (en) 2007-12-13 2008-01-30 Prolysis Ltd Anitbacterial compositions
KR20090098710A (ko) 2008-03-14 2009-09-17 주식회사 씨티아이바이오 세포투과성과 핵산 결합력이 좋은 펩타이드 핵산 유도체
UY32395A (es) 2009-01-27 2010-08-31 Takeda Pharmaceutical Compuesto con anillo fusionado y su uso
US8975389B2 (en) * 2009-03-02 2015-03-10 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
US20120263646A1 (en) 2009-10-15 2012-10-18 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
NZ623384A (en) * 2009-10-16 2016-06-24 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
EP3406613A1 (en) 2009-10-16 2018-11-28 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
EP3404028A1 (en) 2011-04-15 2018-11-21 Melinta Therapeutics, Inc. Methods of making antimicrobial compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060825A1 (en) * 2000-02-17 2001-08-23 Sk Chemicals Co., Ltd. Pyrrolopyrimidinone derivatives, process of preparation and use
CN1871240A (zh) * 2003-08-26 2006-11-29 帝人制药株式会社 吡咯并嘧啶酮衍生物
CN101535311A (zh) * 2006-07-03 2009-09-16 Sk化学株式会社 吡咯并嘧啶酮衍生物的盐及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Synthesis and evaluation of tricyclic pyrrolopyrimidinones as dipeptide mimetics: inhibition of interleukin-1-beta-converting enzyme;Michael C. Laufersweiler,等;《BIOORGANIC&MEDICINAL CHEMISTRY LETTERS》;20050719;第15卷;第4322-4326页 *

Also Published As

Publication number Publication date
CN103958514A (zh) 2014-07-30
WO2012173689A3 (en) 2013-04-04
PT2697229T (pt) 2018-04-13
AR088781A1 (es) 2014-07-10
DK2697229T3 (en) 2018-04-23
JP2014510788A (ja) 2014-05-01
TW201843154A (zh) 2018-12-16
BR112013026410A2 (pt) 2017-06-27
HUE036755T2 (hu) 2018-07-30
EP2697229A2 (en) 2014-02-19
MX2013012015A (es) 2014-10-24
EA201391536A1 (ru) 2014-08-29
CN109053695A (zh) 2018-12-21
ES2665988T3 (es) 2018-04-30
EP3404028A1 (en) 2018-11-21
AU2012271228A1 (en) 2013-11-14
JP2018115206A (ja) 2018-07-26
KR20140065378A (ko) 2014-05-29
MY173518A (en) 2020-01-30
WO2012173689A2 (en) 2012-12-20
US9221827B2 (en) 2015-12-29
EP2697229B1 (en) 2018-04-04
US20190322668A1 (en) 2019-10-24
JP6317669B2 (ja) 2018-04-25
SG194489A1 (en) 2013-12-30
AU2017204803A1 (en) 2017-07-27
MX357903B (es) 2018-07-30
US20140163049A1 (en) 2014-06-12
AU2012271228B2 (en) 2017-04-13
PH12013502135A1 (en) 2022-10-26
TWI656123B (zh) 2019-04-11
EP2697229A4 (en) 2014-09-10
AU2019204745A1 (en) 2019-07-18
SG10201603027QA (en) 2016-05-30
TW201305172A (zh) 2013-02-01
IL228845A0 (en) 2013-12-31
CA2833169A1 (en) 2012-12-20

Similar Documents

Publication Publication Date Title
CN103958514A (zh) 抗微生物化合物及制备和使用所述化合物的方法
US10815238B2 (en) Antimicrobial compounds and methods of making and using the same
KR101972992B1 (ko) 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
US10947237B2 (en) Antimicrobial compounds and methods of making and using the same
US11999739B2 (en) Antimicrobials methods of making and using the same
US20190194205A1 (en) Antimicrobials and methods of making and using same
US10934295B2 (en) Antimicrobials and methods of making and using same
NZ715818A (en) Antimicrobial compounds and methods of making and using the same
NZ715818B2 (en) Antimicrobial Compounds And Methods Of Making And Using The Same
HK1195061A (en) Antimicrobial compounds and methods of making and using the same
HK1195061B (en) Antimicrobial compounds and methods of making and using the same

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20180703

Termination date: 20200411

CF01 Termination of patent right due to non-payment of annual fee